Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer. FOLFOXIRI +贝伐单抗与mFOLFOX6 +贝伐单抗作为转移性结直肠癌一线治疗的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-29 DOI: 10.1080/14737167.2025.2509706

Tong Liu, Yao Yao, Bingjie Liu, Xue Teng, Mei Dong, Xin Zhang

{"title":"Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer.","authors":"Tong Liu, Yao Yao, Bingjie Liu, Xue Teng, Mei Dong, Xin Zhang","doi":"10.1080/14737167.2025.2509706","DOIUrl":"10.1080/14737167.2025.2509706","url":null,"abstract":"Objectives: We first evaluated the cost-effectiveness of the FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as the first-line treatment of metastatic colorectal cancer from healthcare system perspective.Methods: A partitioned survival model was developed to assess the costs and effects of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab. Health outcomes were measured in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). The evaluation of the Chinese healthcare payer perspective was performed across a lifetime horizon, encompassing direct medical expenses.Results: The estimated cost for FOLFOXIRI plus bevacizumab treatment was 9306.364USD, which was higher than 8218.436 USD estimated for mFOLFOX6 plus bevacizumab, leading to an ICER of 1961.857 USD per QALY. One-way sensitivity analysis suggested the body surface area (BSA), the cost of irinotecan, and the cost of fluorouracil had the largest impact on the ICER. The cost-effectiveness acceptability curves showed the probability of FOLFOXIRI plus bevacizumab being cost-effective was100% at a threshold of 12 300 USD per QALY.Conclusion: FOLFOXIRI plus bevacizumab had an economic advantage compared to mFOLFOX6 plus bevacizumab as the first-line treatment of metastatic CRC in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit. 心肾和代谢性疾病患者的临床和经济结果：一个意大利当地卫生单位的现实世界分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-28 DOI: 10.1080/14737167.2025.2504944

Valentina Perrone, Domenica Daniela Ancona, Marco Gnesi, Valentina Mongelli, Sara Migliaccio, Felice Renato Colanero, Emanuele Antonio Lenoci, Lidia Bonfanti, Melania Leogrande, Maria Cappuccilli, Cataldo Procacci, Luca Degli Esposti

{"title":"Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit.","authors":"Valentina Perrone, Domenica Daniela Ancona, Marco Gnesi, Valentina Mongelli, Sara Migliaccio, Felice Renato Colanero, Emanuele Antonio Lenoci, Lidia Bonfanti, Melania Leogrande, Maria Cappuccilli, Cataldo Procacci, Luca Degli Esposti","doi":"10.1080/14737167.2025.2504944","DOIUrl":"10.1080/14737167.2025.2504944","url":null,"abstract":"Background: This single-center real-world analysis describes the epidemiology, demographic and clinical characteristics, mortality, and therapeutic-care management of patients grouped by the presence of seven cardiorenal and metabolic diseases.Research design and methods: From the administrative databases of a single Local Health Unit in Southern Italy with approximately 400,000 inhabitants, the following cohorts were identified during 2020-2021: (1) type 1 diabetes (T1D); (2) type 2 diabetes (T2D); (3) heart failure (HF); (4) chronic kidney disease (CKD); (5) hyperkalemia (HK); (6) nonalcoholic steatohepatitis (NASH); (7) dyslipidemia. The variables examined for each cohort were: prevalence, demographic and clinical data, comorbidity profile, biochemical tests, hospitalization rates, therapies, 1-year all-cause mortality.Results: From a cohorts overview, the population with cardiorenal and metabolic diseases was characterized by a high proportion of elderly subjects, a relatively high rate of all-cause hospitalizations and elevated mortality. The analysis of the comorbidity pattern in each group confirmed the interrelation of these pathologies, with diabetes, dyslipidemia, and CKD as the most common concomitant conditions.Conclusions: From these real-world data, patients with cardiorenal and metabolic diseases emerge as a fragile population, with multimorbidity, and a substantial risk of hospitalizations and death, confirming as chronicity represent a priority issue for health systems.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the psychometric properties of the fatigue severity scale: results from a systematic review and reliability meta-analysis. 探索疲劳严重程度量表的心理测量特性：来自系统回顾和可靠性荟萃分析的结果。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-28 DOI: 10.1080/14737167.2025.2511128

Ilaria Ruotolo, Andrea Carenza, Giovanni Sellitto, Rachele Simeon, Francescaroberta Panuccio, Andrea Marini Padovani, Emanuele Amadio, Alessandro Ugolini, Anna Berardi, Giovanni Galeoto

{"title":"Exploring the psychometric properties of the fatigue severity scale: results from a systematic review and reliability meta-analysis.","authors":"Ilaria Ruotolo, Andrea Carenza, Giovanni Sellitto, Rachele Simeon, Francescaroberta Panuccio, Andrea Marini Padovani, Emanuele Amadio, Alessandro Ugolini, Anna Berardi, Giovanni Galeoto","doi":"10.1080/14737167.2025.2511128","DOIUrl":"10.1080/14737167.2025.2511128","url":null,"abstract":"Introduction: Fatigue is a multifactorial phenomenon that affects individuals across several conditions. Fatigue Severity Scale (FSS) is a widely used questionnaire to measure perceived fatigue. This systematic review aims to identify the psychometric properties of FSS across different populations where it has been validated.Methods: The study selection process was conducted from April 2024 to January 2025. The databases used to identify included studies were MEDLINE (via PubMed), SCOPUS, Web of Science, and CINAHL (via EBSCO). The risk of bias was evaluated using the COSMIN checklist. For the meta-analysis, studies reporting the internal consistency of the scale were analyzed.Results: At the end of the selection process, 59 articles were included in the review; the sample sizes ranged from 20 to 2017 participants, and the mean age spanned from 21,86 to 68,1 years.Conclusion: The FSS is a valid and reliable instrument for fatigue assessment. It would be desirable to investigate heterogeneity; it would be beneficial to investigate responsiveness and to explore the settings in which it is used. Another advise would be to calculate cutoff in healthy subjects to better understand fatigue symptoms and the differences in perception between populations.Registration: PROSPERO (CRD42025635211).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-16"},"PeriodicalIF":1.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece. 希腊转移性去势抵抗性前列腺癌患者的医疗资源利用及相关费用

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-23 DOI: 10.1080/14737167.2025.2505726

E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias

{"title":"Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.","authors":"E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias","doi":"10.1080/14737167.2025.2505726","DOIUrl":"https://doi.org/10.1080/14737167.2025.2505726","url":null,"abstract":"Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.Methods: A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.Results: HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.Conclusions: Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. 在美国，lecanemab对早期阿尔茨海默病医疗保险受益人的预算影响：一个亚组分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-22 DOI: 10.1080/14737167.2025.2507427

Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby

{"title":"Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis.","authors":"Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby","doi":"10.1080/14737167.2025.2507427","DOIUrl":"10.1080/14737167.2025.2507427","url":null,"abstract":"Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibodies. With an economic burden surpassing $345 billion, $222 billion borne by Medicare and Medicaid, this study evaluates lecanemab's budgetary impact for early AD, including subgroup analyses by gender and race.Methods: A budget impact model evaluated LECA for early Alzheimer's disease, comparing scenarios with and without the therapy. Inputs included market share, costs, duration, and compliance. Gender and race subgroup analyses, annual costs, PMPM, PTMPM, and sensitivity analysis outcomes were assessed to explore parameter-driven variability comprehensively.Results: Introducing LECA for over 3.5 million eligible early AD patients in the U.S. may generate a three-year budget impact of $4.1 billion for Medicare. Incremental PMPM savings were $1.4, and PTMPM savings reached $24.1. Subgroup analyses revealed no significant gender or racial differences in PMPM and PTMPM, with variability only in overall budget impact. Sensitivity analyses indicate that enhanced healthcare resource utilization, reduced disease severity, and improved cost-efficiency among males contribute to strengthening Medicare's budget sustainability.Conclusions: Utilizing LECA as a treatment for early AD is expected to be cost saving with respect to Medicare budgets in the U.S.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic and developmental impacts of FDA designations: a systematic review and meta-analysis. FDA指定的经济和发展影响：系统回顾和荟萃分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-21 DOI: 10.1080/14737167.2025.2507426

Joab Williamson, Syed Shahzad Hasan, Vijay S Gc

{"title":"Economic and developmental impacts of FDA designations: a systematic review and meta-analysis.","authors":"Joab Williamson, Syed Shahzad Hasan, Vijay S Gc","doi":"10.1080/14737167.2025.2507426","DOIUrl":"10.1080/14737167.2025.2507426","url":null,"abstract":"Introduction: U.S. FDA designations: Breakthrough Therapy (BTD), Fast Track (FTD), Orphan Drug (ODD), and Regenerative Medicine Advanced Therapy (RMAT) aim to expedite drug development, yet their combined economic and developmental effects have not been extensively studied. This systematic review evaluates their impacts on Day 1 cumulative average abnormal returns (CAAR) and timelines from Investigational New Drug submission to approval.Methods: A systematic search of PubMed, Scopus, ScienceDirect, GreyNet, OpenGrey, ProQuest, and Cochrane Library was conducted for articles published between January 1997 and September 2024. A random-effects model generated pooled estimates with 95% confidence intervals (CI), and heterogeneity was assessed using the Cochrane-Q and I2 statistic. Study quality was evaluated using Drummond's checklist and an adapted Barker checklist.Results: Twenty-five studies were included. The pooled Day 1 CAAR across designations was 6.12% (95% CI: 3.64-8.61). Subgroup analysis revealed FTD with the strongest immediate market impact (8.20%%, 95% CI: 4.38-12.03) and BTD with the shortest mean approval timeline (69.96 months, 95% CI: 60.25-79.67).Conclusions: FDA designations provide economic advantages, especially for smaller companies, and can expedite approvals for high-priority therapies. Notable heterogeneity, particularly with RMAT, warrants further research to clarify how disease area and company size shape real-world outcomes.Registration: ResearchRegistry ID11080.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China. 中国慢性阻塞性肺疾病中重度加重对临床预后和经济负担的影响

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-19 DOI: 10.1080/14737167.2025.2507425

Lei Gan, Xiaoning He, Jing Wu

{"title":"Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China.","authors":"Lei Gan, Xiaoning He, Jing Wu","doi":"10.1080/14737167.2025.2507425","DOIUrl":"10.1080/14737167.2025.2507425","url":null,"abstract":"Objectives: Different severities of exacerbations of chronic obstructive pulmonary disease (AECOPD) will lead to different disease progression and economic burden. This study aimed to evaluate the impact of the severity of AECOPD on disease burden.Methods: Data were from the Tianjin Urban Employee Basic Medical Insurance Database (2016-2020). COPD patients were stratified by severity of AECOPD: (A) no AECOPD, (B) moderate AECOPD only; and (C) ≥1 severe AECOPD. Key outcomes included rate of AECOPD, mortality, COPD-related cost. Sensitivity analysis of reducing the impact of COVID-19 in outcomes was conducted.Results: 6738 patients were identified, with 22.5% for Group A, 41.1% for Group B and 36.4% for Group C. During 1st follow-up year, Group C experienced an average of 1.43 severe AECOPD, leading to a notably increased all-cause mortality (Group C vs A-B: 17.7% vs. 2.6-3.4%, p < 0.001), highest COPD-related costs (CNY 30,245 vs 1,700-6,923). In the second year, patients in Group C still had a highest rate of severe AECOPD (0.44 vs 0.08-0.11 vs, p < 0.001), as well as increased all-cause mortality.Conclusion: Severe AECOPD significantly increased mortality rates and economic burden in the current and subsequent year. This underscored the imperative need to enhance severe AECOPD management.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Valuing prevention: lessons and recommendations from a Dutch expert committee. 重视预防：荷兰专家委员会的经验教训和建议。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-15 DOI: 10.1080/14737167.2025.2504946

Adriënne Rotteveel, Saskia Knies, Ardine de Wit, Johan Polder, Bram Wouterse

{"title":"Valuing prevention: lessons and recommendations from a Dutch expert committee.","authors":"Adriënne Rotteveel, Saskia Knies, Ardine de Wit, Johan Polder, Bram Wouterse","doi":"10.1080/14737167.2025.2504946","DOIUrl":"https://doi.org/10.1080/14737167.2025.2504946","url":null,"abstract":"Introduction: Countries have been struggling with investments in prevention. How to obtain insight in the costs, benefits, and budgetary impacts of investments in prevention? And how to weigh investments in prevention against other investments in health, such as in curative health care. In the Netherlands, in 2023, a methodological expert committee was established to answer such questions. Their advice, published in January 2024, has been impactful, receiving much attention in Dutch politics and policy and leading to the establishment of a subsequent scientific committee on appropriate evidence and the development of an investment model for prevention.Areas covered: In this perspective, we present the main recommendations from the advice and embed these recommendations in the Dutch institutional context. Furthermore, we highlight why the financing of prevention is challenging and suggest some solutions. Finally, we discuss how the advice was received and what follow-up was given, reflect on why this advice had such a large impact, and distill recommendations for other countries from this experience.Expert opinion: Economic evaluation of prevention is not intrinsically more challenging than that of other health investments. For a direct comparison of investments in health, similar methods should be used for both prevention and medical care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis. 中欧和东欧国家多发性硬化症患者获得药物、护理和服务的比较分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-15 DOI: 10.1080/14737167.2025.2493131

Yoana Seitaridou, Dominik Grega, Sorin Paveliu, Agnes Männik, Przemysław Holko, Ivana Tadić, Ivana Stevic, Teodora Chamova, Guenka Petrova, Maria Kamusheva

{"title":"Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis.","authors":"Yoana Seitaridou, Dominik Grega, Sorin Paveliu, Agnes Männik, Przemysław Holko, Ivana Tadić, Ivana Stevic, Teodora Chamova, Guenka Petrova, Maria Kamusheva","doi":"10.1080/14737167.2025.2493131","DOIUrl":"10.1080/14737167.2025.2493131","url":null,"abstract":"Background: The study compared access to disease-modifying treatments (DMTs), care, and services for multiple sclerosis (MS) patients across six Central and Eastern European Countries (CEECs).Research design and methods: A 2-part questionnaire-based survey was conducted among experts from Bulgaria, Estonia, Poland, Romania, Serbia, and Slovakia over 4 months (1 December 2022 - 1 April 2023).Results: The study reveals notable variations in the legal requirements for pricing and reimbursement of MS medications, as well as criteria for health technology assessment (HTA) across countries. Despite these differences, DMTs were fully reimbursed in all countries. Poland exhibited the highest MS expenditures in 2021, totaling 171 million euros. Administrative procedures for prescribing and dispensing MS drugs were similar across countries, but the range of services and support offered to MS patients varied. Assessment of treatment accessibility, based on the number of authorized DMTs listed in Positive Drug Lists (PDLs), shows Bulgaria leading with 84.21% access, followed closely by Poland and Slovakia with comparable rates of 78.95%.Conclusions: The study revealed disparities in health care and services for MS patients across the countries surveyed. Addressing these disparities and the need for targeted interventions to ensure equitable access is critical. Further research is needed to find effective solutions.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review. 呼吸道合胞病毒（RSV）孕产妇免疫经济评价研究中的疾病负担估算：系统综述

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-14 DOI: 10.1080/14737167.2025.2498663

Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez

{"title":"Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review.","authors":"Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez","doi":"10.1080/14737167.2025.2498663","DOIUrl":"10.1080/14737167.2025.2498663","url":null,"abstract":"Introduction: Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informing health economic evaluations (HEE). This review evaluates how HEE of RSV maternal vaccination (MV) estimated the RSV disease burden.Methods: A systematic search was conducted in MEDLINE, SCOPUS, EMBASE, NHS EED, HTA, Tufts CEA Registry, LILACS, and Web of Science for full HEE of RSV MV. Reporting quality was assessed with the CHEERS 2022 checklist, costs were converted to 2024 U.S. dollars, and a descriptive, interpretive synthesis of the data was performed.Results: All 21 included studies were cost-utility analyses, 10 conducted in high-income countries. The HEE utilized a wide range of data sources to build epidemiological estimates, frequently relying on non-local data, particularly for outpatient rates. National data on RSV hospitalization rates were the most commonly available. No study included equity assessments. The maternal vaccine dose price was identified as a critical factor in the strategy's cost-effectiveness.Conclusion: Enhancing local data availability for RSV, by strengthening the respiratory virus surveillance, is crucial to improve the reliability of HEE of RSV prevention strategies and enable more informed and effective policy decisions.Registration: PROSPERO: CRD42024549989.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-34"},"PeriodicalIF":1.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0